**GPU-accelerated agent-based molecular pathway simulations (cancer therapy design) will exhibit coalition-based equilibrium deviations (beyond Nash) when modeling drug-resistant subclonal interactions, where rare cell populations act as coordinated "deviator coalitions" to evade therapeutic pressure.**
Adversarial Debate Score
55% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
Supporting Research Papers
- Towards In Silico Cancer Therapy Design: An Agent-Based Approach for GPU-Accelerated Molecular Pathway Simulation
Agent-based modelling is gaining recognition as a powerful approach for simulating complex cellular pathways, owing to its ability to reproduce emergent biological behaviours without requiring extensi...
- A Novel Stochastic Particle-Field Algorithm for a Reaction-Diffusion-Advection Cancer Invasion Model
In this paper, we present a novel numerical framework for solving a specific biological reaction-diffusion-advection system of cancer growth in three dimensions (3D) using particles of variable mass. ...
- A Mathematical Model for Chemotherapy, Immunotherapy and Virotherapy Treatments of Cancer
We continue our study of a model for cancer treatment, constructed in Dutta et. al., 2025, by adding Virotherapy to the Chemotherapy and Immunotherapy studied there. It is a dynamical system model for...
- A quantitative model for the emergent population dynamics of the melanoma MITF rheostat
Cancer progression is driven by the ability of cells with identical driver mutations to adopt biologically distinct adaptive phenotypes. Yet the population dynamics implied by intratumour phenotypic h...
- Drug Synergy Prediction via Residual Graph Isomorphism Networks and Attention Mechanisms
In the treatment of complex diseases, treatment regimens using a single drug often yield limited efficacy and can lead to drug resistance. In contrast, combination drug therapies can significantly imp...
Computational Result
An LLM's reading of the literature — not computational verification.
Coalition behavior in drug resistance remains uncertain and requires further investigation.
Method: literature_meta · Result: inconclusive · Confidence: 60%
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
In GPU-accelerated agent-based models (ABMs) of tumor subclonal populations under therapeutic drug pressure, rare drug-resistant subclones will exhibit emergent "coalition-like" behaviors — statistically correlated, mutually reinforcing strategy shifts (e.g., synchronized phenotype switching, paracrine signaling coordination, or metabolic resource-sharing) — that produce population-level equilibria deviating from the Nash equilibrium predicted by an equivalent non-cooperative game-theoretic model of the same pathway network. Specifically: the empirical steady-state distribution of resistant vs. sensitive subclone fractions under fixed drug dosing will differ from the Nash-predicted distribution by an effect size ≥0.2 (Cohen's d) in ≥60% of parameter regimes tested, and this deviation will be reducible (partially explained, R²≥0.3) by a coalition-formation model (e.g., cooperative game / core-based solution concept) fit to the same simulation trajectories.
- If, across ≥80% of tested parameter regimes, the ABM steady state matches the Nash-equilibrium prediction within effect size <0.1 (Cohen's d), the hypothesis is disproven for that mechanism class.
- If a coalition-based (cooperative game / core / Shapley-value) model fit to the same trajectories explains no more variance (ΔR² ≤ 0.05) than a null model with added noise terms, the "coalition" framing is disproven as explanatorily useful (deviation may still exist but isn't coalition-structured).
- If deviations disappear when inter-agent communication/signaling channels are ablated (control condition) at a rate inconsistent with a coalition mechanism (i.e., deviation persists without any communication channel), the causal claim is disproven.
- If results are only reproducible under one specific random seed / initialization and fail a pre-registered replication (n=30 seeds, Bonferroni-corrected), disproven as a numerical artifact.
Spine & Adversarial ReadReady for validation
“This hypothesis tests whether spatial agent-based tumor simulations incorporating inter-subclonal signaling produce steady-state resistant/sensitive population distributions that deviate from classical Nash-equilibrium predictions in a manner statistically attributable to coalition-like cooperative dynamics among resistant subclones.”
- highEvolutionary game theory in oncology (Gatenby, Brown, Basanta, and others) has for over a decade modeled frequency-dependent, non-Nash, ecologically-structured resistance dynamics; 'coalition deviation from Nash' may just be a relabeling of well-established spatial evolutionary game effects (kin selection, spatial reciprocity) without genuine new content.Unresolved in this EVP due to unavailable literature search — CLOSEST_EXISTING_WORK is empty because no search results were retrievable, not because none exist. This is a critical gap: before funding, a proper search of the adaptive-therapy/evolutionary-game-oncology literature (e.g., Moffitt Cancer Center group, Kaznatcheev's work on cancer game theory) must be conducted to determine if 'coalition-based deviation' is already a named, modeled phenomenon under a different term (e.g., 'group selection' or 'public goods games in cancer').
- highWhy is a cooperative-game/Shapley-value framework the correct formalization of 'coalition behavior' rather than simpler alternatives (spatial correlation statistics, mean-field approximations with higher-order moments, or standard evolutionary game theory with added interaction terms)? The methodology does not justify why the cooperative game-theoretic lens adds explanatory value over already-standard spatial/frequency-dependent game models.Partially addressed via the ablation design (shuffled-signal control) which does test causal structure, but the choice of Shapley value/core as THE coalition metric (vs. e.g., simpler mutual-information or Granger-causality-based coordination metrics) is not independently justified. Protocol should be revised to include a model-comparison step against at least one non-cooperative-game null (e.g., higher-order mean-field model) to show the cooperative-game framing specifically outperforms simpler explanations, not just a noise null.
- mediumThe 'rare cell populations acting as coordinated deviator coalitions' framing anthropomorphizes what may be purely emergent, non-intentional local optimization (each cell responding only to local gradients) — labeling this 'coalition' behavior may overclaim strategic coordination that doesn't exist at the mechanistic level.Addressed by disproof criteria requiring the cooperative-game model to add explanatory power beyond noise, but the philosophical distinction between 'emergent local optimization' and 'coalition' is not resolved — the EVP should explicitly state that 'coalition' is used as a mathematical/game-theoretic descriptor of outcome structure, not a claim about cellular intentionality, to preempt this critique in review.
Experimental Protocol
Minimum viable test (MVT):
- Build a spatial ABM (2D lattice, ~5,000–50,000 agents) of a single canonical resistance pathway (e.g., EGFR/MAPK with a known bypass mechanism, or AR-pathway prostate cancer resistance) with 3 agent types: drug-sensitive, resistant, and intermediate/persister.
- Implement a paracrine signaling channel (diffusible factor) enabling local cooperative benefit (e.g., resistant cells secreting a factor that protects neighboring sensitive cells — a documented biological phenomenon).
- Run the ABM under fixed dosing to steady state (GPU-accelerated, e.g., via CUDA/JAX/Taichi) for 200 parameter combinations (dose × diffusion range × cooperation strength × initial resistant fraction).
- In parallel, formulate an equivalent non-cooperative evolutionary game (replicator dynamics / normal-form game) using the same fitness payoffs stripped of spatial/signaling coupling; compute its Nash equilibrium analytically or via best-response iteration.
- Compare ABM steady-state distributions to Nash predictions; fit a cooperative-game solution concept (Shapley value allocation, core stability test) to ABM trajectories.
- Run ablation controls: (a) zero signaling range, (b) randomized/shuffled signaling (breaks coordination but preserves magnitude), (c) increasing agent count 10×/100× to test finite-size effects.
- No patient data required for MVT (synthetic ABM only). For extended validation: publicly available subclonal evolution datasets (e.g., TRACERx lung cancer multi-region sequencing, PCAWG resistance mutation timelines) to calibrate agent fitness/mutation parameters.
- Pathway topology from a curated source (Reactome, KEGG) for the chosen cancer pathway (e.g., EGFR-TKI resistance in NSCLC).
- Reference resistance-mechanism literature (e.g., documented paracrine/exosome resistance-transfer papers) to justify coupling term parameterization — must be logged as assumptions, not fit-free.
- Simulation framework: existing open-source spatial ABM engine (e.g., PhysiCell, CompuCell3D) or custom GPU kernel (JAX/Taichi) — required as software dependency, not dataset per se.
- ≥60% of 200 parameter regimes show Cohen's d ≥0.2 deviation from Nash prediction (p<0.05, FDR-corrected).
- Cooperative-game model achieves R²≥0.3 in explaining ABM deviation patterns, with ΔR² ≥0.15 over null noise model.
- Ablation confirms causal dependency: zero-signaling-range condition reduces deviation effect size by ≥50% relative to full-signaling condition.
- Results replicate across ≥2 independent ABM engines/implementations with consistent direction of effect (same sign, overlapping CIs).
- <30% of regimes show meaningful deviation, OR cooperative model R²<0.1, OR ablation shows no reduction in deviation when signaling is removed (implies deviation is a numerical/finite-size artifact, not coalition behavior).
- Effect fails to replicate across seeds (CI crosses zero in >50% of bootstrap resamples).
- Effect fails to replicate across independent ABM implementations (software-specific artifact suspected).
ROI Projection
Direct application to oncology drug-combination simulation platforms (e.g., in silico trial design tools used by pharma for resistance modeling). A validated coalition-detection module could be licensed as an add-on to existing ABM/digital-twin cancer simulation platforms. Broader value: the coalition-game analytical framework generalizes to any multi-agent adaptive system with rare coordinated defectors (antimicrobial resistance, immune evasion modeling) — cross-domain reusability increases commercial surface area beyond oncology alone.
TIME_TO_RESULT_DAYS: 75
Implementation Sketch
# GPU ABM core (pseudocode, JAX/Taichi-style) class SubcloneABM: agents: array[N, state] # state: {type, position, fitness, resistance_level} signal_field: grid[X,Y] # diffusible paracrine factor concentration def step(dt): signal_field = diffuse(signal_field, D) + secrete(agents) local_signal = sample(signal_field, agents.position) fitness = base_fitness(agents.type, drug_dose) + coop_bonus(local_signal) agents = reproduce_and_die(agents, fitness, dt) # vectorized on GPU agents = mutate(agents, mutation_rate) return agents, signal_field # Nash equilibrium comparator def compute_nash(payoff_matrix): return replicator_dynamics_fixed_point(payoff_matrix) # or best-response iteration # Coalition-fit analysis def fit_coalition_model(abm_trajectories): shapley_values = compute_shapley(abm_trajectories, characteristic_function) core_stability = test_core(abm_trajectories) r2 = compare_variance_explained(abm_trajectories, shapley_values, null_model) return r2, shapley_values # Main sweep for dose, diffusion_range, coop_strength, init_frac in parameter_grid(200): for seed in range(30): traj = run_abm(dose, diffusion_range, coop_strength, init_frac, seed, steps=10000) nash_pred = compute_nash(payoff_from_params(dose, coop_strength)) deviation[dose, diffusion_range, coop_strength, init_frac, seed] = effect_size(traj[-1], nash_pred) fit_coalition_model(all_trajectories) run_ablations(['zero_range','shuffled_signal','scale_10x','scale_100x'])
- Day 15 (after ABM sanity checks): if the ABM does not reproduce basic known qualitative resistance dynamics (e.g., dose-dependent selection for resistance) — abort and revise implementation before full sweep.
- Day 35 (after initial 20% parameter sweep): if <10% of regimes show any deviation trend (d≥0.1), do a pre-registered interim analysis; if trend absent, halt full sweep to save GPU budget.
- Day 55 (after ablations on subsample): if signal-shuffle ablation does not reduce deviation at all, abort further scale-up runs — mechanism is not coalition-based.
NAMED_EXPERTS: []
CLOSEST_EXISTING_WORK: []
NOVELTY_NARROWING_REQUIRED: true